Table 1.
Overview of Studies on Stimulation of Coronary Arteriogenesis. First Column Names the Study, Second and Third Columns Describe the Stimulus Used and Fourth Column Presents the Outcome.
| Trial | Stimulus | Substance/route of Administration | Outcome |
|---|---|---|---|
| Seiler et al. | chemical | GM-CSF (i.c., s.c.) | Increase in coronary collateralization, increase of CFI |
| Belardinalli et al. | chemical | Dipyridamole (p.o.) | Increase in coronary collateralization, combined with exercise |
| VIVA | chemical | rhVEGF (i.c.) | No difference in angina frequency or exercise tolerance |
| AGENT | chemical | Adenoviral FGF4 (i.c.) | Non-significant increase in exercise-time after 4 weeks |
| FIRST | chemical | FGF2 (i.c.) | No difference in exercise tolerance when compared to placebo |
| Zbinden et al. | chemical | GM-CSF (s.c.) | Increase in CFI, terminated when 2 patients developed ACS |
| Meier et al. | chemical | G-CSF (s.c.) | Increase in CFI, more often lack of ST-segment elevation |
| Gloekler et al. | mechanical | ECP | Increased CFI compared to Sham treatment (augmentation of venous return alone) |
| Art.Net.-2 | mechanical | ECP | Increased CFI and FFR, improvement in angina frequency and dyspnea |